WVVIP Willamette reports Q1 2024 022 per share loss as stock gains 364 percent What Cue Biopharma CUE said about economic headwinds Cue Biopharma Beats Forecast Cuts Losses Sharply What Arcellx ACLX subscription metrics reveal about retention Q4 2025 EPS Tops Views Why IB Acquisition IBAC deserves more attention from serious investors 055 20260505